Addex Therapeutics (ADXN) Q2 2026 earnings review
Addex loses its Indivior partnership as cash drops below CHF 1M
Addex Therapeutics generated zero revenue and spent barely anything on research this quarter as its cash reserves dwindled. Operating costs fell 15%, driven by a near-total halt in active drug development. The company raised a small amount of cash by selling treasury shares to keep the lights on.
| Cash and cash equivalents | CHF 767,328 CHF 1.6M at year-end |
|---|---|
| Quarterly operating costs | CHF 655,300 CHF 769,273 a year ago |
| Quarterly research and development | CHF 37,986 CHF 234,454 a year ago |
| Indivior milestone potential | $0 $330M previously expected |
⚖️ Verdict: 🔴🔴 Very Bearish
The story got drastically worse because the company lost its biggest external validation. Indivior terminated its licensing agreement, erasing the potential for up to $330 million in milestone payments that management previously relied on. One slight positive: the company now expects its remaining CHF 767,000 to fund operations into late 2027, an extension achieved purely by stopping clinical work.
The question now is how the company will fund any actual development before it runs out of money entirely. It can seek a new partner for the returned programs or wait for a liquidity event from its external investments. Next quarter's cash flow will show if the current survival mode is sustainable.
🐂 Bull Case
The Cash Runway Stretches To Late 2027
Management expects its existing cash to fund operations through the fourth quarter of 2027, an extension from its prior warning of a mid-2026 cliff. That runway relies on extreme cost-cutting, as the company holds just CHF 767,000 in the bank.
What to watch: the quarterly cash burn rate. A runway estimate means little if the company is not spending enough to advance its pipeline toward a milestone.
🐻 Bear Case
The Indivior Partnership Is Over
Management previously framed the Indivior partnership as a central pillar of the company's value, pointing to $330 million in potential milestones. That narrative ended late in the quarter when Indivior terminated the agreement following a corporate merger, returning the substance-use program to Addex.
The return leaves the company with no active external partnerships generating near-term clinical milestones. The asset joins a list of unpartnered programs that lack the funding to enter human trials.
What to watch: whether Addex can secure a new partner for the returned asset before the market discounts it entirely.
Research Spending Has Nearly Stopped
Research and development costs fell 84% from a year ago to just CHF 38,000 in the second quarter. The financial statements show a company performing almost no active drug development as it waits for new funding.
What to watch: the R&D expense line in future quarters. A rise would signal that the company has secured the capital needed to restart its pipeline.
Risks this quarter didn't answer
The core unpartnered pipeline remains stalled without capital. Three standing items are waiting on funding or external events:
- Chronic cough clinical trials: no new financing to begin required studies.
- Dipraglurant for stroke recovery: remains on hold for the same reason.
- Stalicla investment: no update on the potential IPO or Series C financing mentioned last year.
👓 Other Themes
Neurosterix Continues To Subsidize Operations
Addex is surviving partly because it receives free infrastructure from its spin-out. The company recognized CHF 10,000 in other income this quarter for services received at zero cost from Neurosterix, keeping general expenses lower than they would otherwise be.
💲 Other KPIs
Dilution continues as the company sells stock to stay afloat. Addex sold 9.5 million treasury shares during the half-year, raising about CHF 427,000 in gross proceeds to cover basic operating costs.
Shrinking quickly, down from CHF 6.36 million at year-end. The drop reflects the falling cash balance and the declining carrying value of the company's equity stake in Neurosterix as it recognizes its share of the spin-out's losses.
❓ Key Questions
Funding operations through 2027
How does a bank balance of CHF 767,000 realistically fund operations for another 15 months without grinding all corporate activity to a halt?
The Indivior termination
With the GABAB PAM program returned, what is the strategy to generate non-dilutive capital now that the $330 million in potential milestones is gone?
Stalicla IPO timing
Are there any updates on Stalicla's path to the public markets, given that a liquidity event there is one of the few remaining cash sources?